Effexor (Venlafaxine) Onsite Taper

No. You arrive on your current prescribed venlafaxine dose and the taper is done onsite under continuous cardiac telemetry, bridged with sub-psychoactive full-spectrum iboga total alkaloid at 75–150 mg BID. MindScape does not ask you to attempt a solo washout at home before treatment. A small number of other medications — MAOIs, lithium, tricyclic antidepressants, tramadol and certain QT-prolonging cardiac medications — do still need to be cleared before you arrive, so our medical team reviews your full medication list in advance.

Typically 14–28 days onsite. That range is driven by venlafaxine's short half-life — ≈ 5 hours (parent), 11 hours (O-desmethylvenlafaxine) — and your baseline dose, usually 37.5–375 mg/day. Reductions are hyperbolic rather than linear, so the schedule follows how you actually respond instead of running to a fixed calendar.

The venlafaxine discontinuation profile covers: Severe brain zaps within hours of a missed dose; Dizziness, vertigo, gait instability; Noradrenergic rebound — sweating, hypertension, tachycardia; Anxiety crises, panic surges; GI distress, sleep disruption. The onsite protocol bridges the taper with sub-psychoactive iboga total alkaloid (75–150 mg BID) to cover the receptor-occupancy gap as your dose comes down, with symptom-driven support and continuous monitoring throughout.

Venlafaxine's short half-life means symptoms emerge between doses, not just on taper. The XR formulation is bead-based — patients have to count beads to micro-taper. Both serotonergic and noradrenergic withdrawal components — broader receptor coverage required. BP and HR rebound on taper requires telemetry that home tapers can't provide.

Yes. Bead-counting hyperbolic taper or compounded liquid venlafaxine. Iboga TA bridge 75–150 mg BID — broader receptor coverage matches dual SNRI footprint. Continuous cardiac telemetry with BP and HR monitoring (noradrenergic rebound). Magnesium pre-loading; electrolyte normalization.

A flood dose of ibogaine HCl is only administered once venlafaxine has been reduced to a protocol-defined safe threshold and your cardiac screening is still within limits — eligibility is confirmed at that point rather than promised in advance. Ibogaine is an investigational compound, is not approved by the FDA, and results vary between patients. If your medication picture or your screening makes treatment unsafe, we will tell you honestly.